https://scholars.lib.ntu.edu.tw/handle/123456789/537208
標題: | Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen | 作者: | HONG-YUAN HSU MEI-HWEI CHANG Hsieh R.-P. YEN-HSUAN NI Chi W.-K. |
公開日期: | 1996 | 出版社: | John Wiley and Sons Inc. | 卷: | 24 | 期: | 6 | 起(迄)頁: | 1355-1360 | 來源出版物: | Hepatology | 摘要: | The immune responses to hepatitis B vaccine were studied in 11 hepatitis B surface antigen (HBsAg) carrier children who had cleared HBsAg but failed to develop hepatitis B surface antigen antibodies (anti-HBs) in sera (group 1), 5 HBsAg carrier children who had cleared HBsAg and developed detectable anti-HBs in sera (group 2), and 5 healthy subjects seronegative for all hepatitis B virus (HBV) markers (group 3). After receiving three doses of HB vaccine, group 1 subjects failed to develop detectable anti-HBs. Subsequently, each subject of the three groups was given one dose of the same vaccine for a cellular immunity study, and a measurable proliferation of peripheral blood mononuclear cells (PBMC) to HBsAg was detected in 1 of 8 (12.5%), 0 of 5, and 4 of 5 (80%) of the cases in each group, respectively, after vaccination. The removal of CD8+ cells enhanced the HBsAg blastogenic response in group 3 but did not reverse the unresponsiveness in group 1 and group 2 subjects. The addition of interleukin (IL)-2 in culture reversed unresponsiveness in all cases except one case in group 1. Compared with before vaccination, PBMC from group 2 subjects produced significantly less interferon gamma (IFN-γ) and more IL-4 in response to HBsAg after vaccination, a cytokine response not observed in group 1 subjects. HLA typing indicated that 3 of 10 patients in group 1 (30%) and 1 of 5 patients in group 2 (20%) had HLA-DRw14-DRw52, a marker previously linked to low anti-HBs response to hepatitis B vaccine in Taiwan. We conclude that the underlying causes of poor anti-HBs response in group 1 subjects are multifactorial, including specific failure of antigen presentation or T-cell activation, or the lack of T helper (Th)2 cell-like response to HBsAg. HLA-DRw14-DRw52 does not confer absolute nonresponsiveness to HBsAg. These patients are not benefited by hepatitis B immunization. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029979729&doi=10.1053%2fjhep.1996.v24.pm0008938161&partnerID=40&md5=0c21f1d12e4575b280efa7e8e55dfb84 https://scholars.lib.ntu.edu.tw/handle/123456789/537208 |
ISSN: | 0270-9139 | DOI: | 10.1053/jhep.1996.v24.pm0008938161 | SDG/關鍵字: | CD8 antigen; cytokine; gamma interferon; hepatitis B surface antibody; hepatitis B surface antigen; hepatitis B vaccine; HLA DR antigen; interleukin 2; interleukin 4; recombinant hepatitis B vaccine; adolescent; adult; antibody response; antigen presentation; article; cellular immunity; clinical article; clinical trial; controlled clinical trial; controlled study; dose response; female; helper cell; hepatitis B; Hepatitis B virus; HLA typing; human; human cell; intramuscular drug administration; male; mononuclear cell; priority journal; school child; T lymphocyte activation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。